Awareness of albuminuria in an Italian population-based cohort of patients treated with hypoglycemic drugs

Journal of Nephrology

Volumn 25, Issue 3, 2012, Pages 325-331

  Esposti, Luca Degli ^a   Saragoni, Stefania ^a   Buda, Stefano ^a   Sturani, Alessandra ^b   Quintaliani, Giuseppe ^c   Bartolucci, Sandra ^d   di Turi, Roberta ^e   Lilli, Paolo ^f   Didoni, Guido ^g   Esposti, Ezio Degli ^a  

^a Economics and Outcomes Research   (Italy)

^b POLICLINICO UMBERTO I   (Italy)

^c Perugia Hospital   (Italy)

^d Local Health Unit N8   (Italy)

^e Pharmaceutical Department   (Italy)

^f Local Health Unit 3 Umbria   (Italy)

^g BRISTOL MYERS SQUIBB   (United States)

Author keywords

Albuminuria; Angiotensin receptor blockers; Antihypertensive therapy; Type 2 diabetes

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; CARDIAC AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGED; ALBUMINURIA; ARTICLE; AWARENESS; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE REGISTRY; ETHNIC GROUP; FEMALE; HOSPITAL DISCHARGE; HUMAN; ITALIAN; LABORATORY TEST; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MONOTHERAPY; PATIENT IDENTIFICATION; POPULATION RESEARCH; PRESCRIPTION; REIMBURSEMENT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ALBUMINURIA; ANALYSIS OF VARIANCE; ANTIHYPERTENSIVE AGENTS; ATTITUDE OF HEALTH PERSONNEL; AWARENESS; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; DRUG PRESCRIPTIONS; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; ITALY; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PREVALENCE; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84863305969     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/jn.5000005     Document Type: Article

References (22)

1. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med. 1984;310:356-360.
2. Berrut G, Bouhanick B, Fabbri P, et al. Microalbuminuria as a predictor of a drop in glomerular filtration rate in subjects with non-insulin-dependent diabetes mellitus and hypertension. Clin Nephrol. 1997;48:92-97.
3. Keane WF, Brenner BM, de Zeeuw D, et al; RENAAL Study Investigators. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int. 2003;63:1499-1507.
4. Anavekar NS, Gans DJ, Berl T, et al. Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuria. Kidney Int Suppl. 2004;66:S50-S55.
5. Gerstein HC, Mann JF, Yi Q, et al; HOPE Study Investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286:421-426.
6. de Zeeuw D, Remuzzi G, Parving HH, et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation. 2004;110: 921-927.
7. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2005;28(Suppl 1):S4-S36.
8. Atkins RC, Zimmet P; 2010 International Society of Nephrology/ International Federation of Kidney Foundations World Kidney Day Steering Committee; International Diabetes Federation. Diabetic kidney disease: act now or pay later. J Nephrol. 2010;23:1-4.
9. Brenner BM, Cooper ME, de Zeeuw D, et al; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
10. Lewis EJ, Hunsicker LG, Clarke WR, et al; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
11. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870-878.
12. Mancia G, De Backer G, Dominiczak A, et al; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105-1187.
13. Schmieder RE, Bakris G, Weir MR. Telmisartan in incipient and overt diabetic renal disease. J Nephrol. 2011;24:263-273.
14. Clinical Guidelines Task Force. Global guideline for type 2 diabetes. International Diabetes Federation, 2005. Available at: http://www.idf.org/webdata/docs/IDF%20GGT2D.pdf [p. 56]. Accessed June 20, 2011.
15. Cirillo M. Evaluation of glomerular filtration rate and of albuminuria/ proteinuria. J Nephrol. 2010;23:125-132.
16. Garg AX, Kiberd BA, Clark WF, Haynes RB, Clase CM. Albuminuria and renal insufficiency prevalence guides population screening: results from the NHANES III. Kidney Int. 2002;61:2165-2175.
17. Standl E, Stiegler H. Microalbuminuria in a random cohort of recently diagnosed type 2 (non-insulin-dependent) diabetic patients living in the greater Munich area. Diabetologia. 1993;36:1017-1020.
18. Bruno G, Cavallo-Perin P, Bargero G, et al. Prevalence and risk factors for micro-and macroalbuminuria in an Italian population-based cohort of NIDDM subjects. Diabetes Care. 1996;19:43-47.
19. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317: 703-713.
20. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348: 383-393.
21. Strippoli GFM, Bonifati C, Craig M, et al. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease (Cochrane Review). In: The Cochrane Library. Issue 4. London: Wiley; 2006.
22. Lewis EJ, Hunsicker LG, Clarke WR, et al; Collaborative Study Group. Renoprotective effect of the angiotensinreceptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345: 851-860.